In June 17-20, MMXV est, quod feliciter tenuit 2015th International Conference lymphoma in Helvetia. MMMDCC XC regionibus participatur a repraesentativis in eventu. In conventu, in investigationis de lymphoma egregium, non solum multi-centrum ad a summary randomized dispensata iudiciis, sed de analysis de novo effectus initial medicamento curatio et fama per investigationis eventus pathogenesis, etc., quod sine dubio in diagnosis et diagnosis de lymphoma. Et porro dictum quod curatio, et obtulerunt ei partem in comesationibus eorum usque ad festum CLINICUS.
1. follicularis lymphoma: novi curatio endpoint
progression-free survival (PFS) is the primary endpoint of first-line treatment of follicular lymphoma, but because of the longer follow-up period (expected ≥ 7 years), there are certain limitations . The FLASH team conducted a prospective meta-analysis (abstract number: 122), and the results showed that a complete response at 30 months (CR30) may be the primary endpoint of the first-line treatment study of follicular lymphoma. The study included 13 clinical trials and a total of 3837 patients were available for evaluation. The results showed that the linear correlation coefficient of CR30 and PFS at the trial level was 0.88, and the Copula model correlation coefficient was 0.86; the risk ratio at the patient level was 0.703. In the subgroup with invasive disease (stage IV or high FLIPI score), the correlation between the two is more obvious.
2. Hodgkin scriptor lymphoma: curatio medium-terminus sequi-CT DELICIUM
The international multi-center prospective RATHL study (abstract number: 008) included 1214 patients with newly-treated adult Hodgkin lymphoma, all of which were stage ⅡB-Ⅳ, or ⅡA combined with large masses, or ≥3 affected sites. All patients were given 2 cycles of ABVD chemotherapy followed by PET-CT (PET2). PET2 negative patients were randomly given 4 cycles of ABVD regimen or AVD regimen chemotherapy, and then entered the follow-up period. PET2-positive patients were given 4-cycle BEACOPP-14 regimen or 3-cycle enhanced BEACOPP regimen chemotherapy, and then performed PET-CT examination again (PET3); PET3-negative patients continued to receive 2-cycle BEACOPP-14 regimen or 1-cycle enhanced BEACOPP regimen chemotherapy; Patients with PET3 positive were given radiotherapy or salvage chemotherapy. Regardless of whether there is a large mass at baseline or whether there are residual lesions after treatment, if the mid-term PET-CT test is negative, no radiotherapy will be given. Results PET2 was negative in 84% of patients, with a median follow-up of 32 months, 3-year PFS was 83%, and overall survival rate (OS) was 95%. The 3-year PFS of the ABVD regimen group and the AVD regimen group were similar (85.45% and 84.48%, respectively), and the 3-year OS was not statistically different (97.0% and 97.5%, respectively), but the lung toxicity of the ABVD regimen was significantly higher than that of AVD The protocol suggests that it is safe and effective to remove bleomycin in the ABVD protocol.
3. Prima systematis nervosi centralis de lymphoma: et Titipe rituximab virtutis incremento
IELSG32 multi-centrum internationalis est futurum tempus iudicii II (numerum, IX), comprehendo systematis nervosi centralis CCXXVII aegris cum nuper-tractata prima lymphoma, cum medianus aetatis suae annis LVIII (009-227 annos). Passim dividitur in tribus coetibus: Group A IV datum cursus MTX 58G / m18 (D70), C Ara-4g / m3.5 (d2-1); Group B datum rituximab 2mg / m2 (d 2, d3); Group C datum Titipipe XXX mg / m375 (d2) in ex Group B; Rectum dividitur totum cerebrum fortuite qui operatur cum grege carmustine Titipi Pretreatment caule cellam translationi cum autologous elit. Results In summa effective rates per tres coetibus et LIII%, LXXIV% et LXXXVII% ^, CR jungantur rates esset XXIII%, XXXI%, et XLIX% et V annos defectum, gratis salvos rates in XXXIV%, XLIII%, et LIV%, respective. OS quod erat XXVII%,% L et LXVI% habuisse dicimus conditores, addendo nihil ad rituximab titipe et curatio consilium ad amplio significantly can amplio efficaciam et longa-term deploratae.
4. Antigen chimeric T cellula precursor (CAR-T) curatio: initial results
CTL019 car-cellulis et T cellulis targeting CD19 bonam ostendere anti-tumore effectus in patientibus leukemia portu et aversantibus. A orci tempus iudicii II (numerum, CXXXIX) verificatur in curatio efficaciam de CD139-positivum non-amet CTL019 Hodgkin scriptor lymphoma. XXIX De studium includitur in portu durum lymphoma aegris, inter XIX magna casibus B-cell lascivae orationis et lymphoma, follicular lymphoma VIII casibus et II casibus de Lymphom pallium suum. Mediana LVI annorum aetatem est. 19-29 dies post chemotherapy, V × CVIII CTL19 intravenously cellulis sunt data. Results quod LXVIII% totalis efficax rate erat. Inter eos, in rate of C. large diffusa esse B-XLII% Lymphom et partiali remissione (R) VIII% rate erat; C. LVII% ad rate of folliculorum lymphoma autem erant et in quinque XLIII% rate. XV aegris developed cytokine release syndrome. Cum medianus sequantur, ex VI mensibus, PFS est LIX%. Lorem consilium CTL8 cellula est tutum et efficax.
Duplex B-5-percutiens large diffuso in Lymphom: in vitro et in vivo Selinexor est effective
Selinexor est oris precursor nuclei export electionem selectivam, XPO1 vetat obscura, ac Favet nuclei retention of activation tumor suppressor proteins magis quam X, et reduces myc, et BCL10 c / VI nuclei retention of dapibus per gradus EIF2E. In test esse in vitro (numerum: CXLVI), Selinexor machinationem inhibendi ius est bonum effectum in quod influat duplici percutiens large-B-cell Lymphom linea DoHH6 et habet bonum effectum in machinationem inhibendi ius MYC BCL4 mutant seu cellula lineae. In orci iudicium Phase I: VI aegris Selinexor curatio receperunt et remissione III aegris effectum, fuit confirmatus in quibus patientes estote I Pet ad CK, CT et accepit aegris II Pr.
In praeter, in de longos Index prognosticon fuisse Lymphom lymphocytic leukemia et pallio deponite, de quibus etiam in hoc colloquio et resolvitur, et vitiatam orci Indicatores ad iudicare eius praesentati sunt longa-term deploratae; Ordo Mundi Health Organization MMXVI et lymphoma est updated contentus editionis decreta et munera data in antecessum ad colloquium. In brevi, hoc tempus ad coadunandos magnam res in libro de hebdomadibus novus directionem ad diagnosis et curatio lymphoma, et ad optimize certe amplius curatio individuata, secundum quod fundatur medicina.
